Sunvozertinib for untreated NSCLC with EGFR rare mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer (NSCLC) that is not squamous type.
- Your cancer has an uncommon change (mutation) in the EGFR gene, but not the common ones like exon 19 deletion, L858R, T790M, or exon 20 insertions.
- You have not had any prior cancer treatment for advanced disease.
- You have at least one tumor that can be measured on scans (according to RECIST 1.1).
- You are expected to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy, sunvozertinib, for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to previous treatments. It may be an option if you have already tried chemotherapy and an EGFR-targeting drug.
This trial tests the drug sunvozertinib given after surgery to see if it prevents lung cancer from coming back. It is for people with early-stage non-small cell lung cancer that has specific changes in the EGFR gene (exon20 insertion or PACC mutations).
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
This trial tests a new pill (sunvozertinib) combined with chemotherapy for people with a specific EGFR mutation type of lung cancer whose previous targeted pill stopped working. It aims to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.